Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT06144086
PHASE2

A Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia (OP-724-H201)

Sponsor: Kiminori Kimura, MD

View on ClinicalTrials.gov

Summary

This is a phase 2 trial of foscenvivint in liver cirrhosis patients caused by HIV/HCV co-infection with hemophilia to evaluate the efficacy, safety and pharmacokinetics.

Official title: A Multi-center, Single-arm, Open-label Phase 2 Trial of Foscenvivint in Liver Cirrhosis Patients Caused by HIV/HCV Co-infection with Hemophilia

Key Details

Gender

MALE

Age Range

18 Years - 74 Years

Study Type

INTERVENTIONAL

Enrollment

6

Start Date

2024-05-08

Completion Date

2026-03-31

Last Updated

2025-03-17

Healthy Volunteers

No

Conditions

Interventions

DRUG

Foscenvivint

Administered by intravenous (IV) infusion over 3-4 hours

Locations (3)

Hokkaido University Hospital

Sapporo, Hokkaido, Japan

National Hospital Organization Osaka National Hospital

Osaka, Osaka, Japan

Tokyo Metropolitan Komagome Hospital

Bunkyo-Ku, Tokyo, Japan